Challenges Prompt Diagnostics Footprint Change At Siemens Healthineers
Company bids to reduce business complexity
Executive Summary
Siemens Healthineers reported strong increases revenues and order bookings for its fiscal 2022, but it is realigning its radiation oncology businesses and changing its IVD business structure.
You may also be interested in...
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.